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639REPLY: Transradial PCI in Women:
Zeroing in on CrossoversWe thank Drs. Chugh and Chugh for their interest
in our work (1) and for their comments. We agree
that access failure remains a limitation of trans-
radial intervention (TRI). As demonstrated in
SAFE-PCI for Women (Study of Access Site for
Enhancement of PCI for Women) trial, radial artery
spasm (RAS) is a major contributor to access site
crossover from radial to femoral. Women generally
have smaller radial arteries, and as the authors
suggest, arterial-sheath size mismatch might cause
RAS. Our protocol did not recommend sizes for
sheaths/catheters, nor did we routinely collect this
information, limiting our ability to explore this
hypothesis in our female population. Data suggest
that most U.S. operators use 5-F or 6-F sheaths for
diagnostic catheterization and 6-F sheaths for cor-
onary intervention (2). More slender equipment
might reduce RAS in women. However, our access
site crossover rate was consistent with that from
the RIVAL (Radial versus Femoral Access for Coro-
nary Intervention) trial, which studied a predomi-
nantly male population (3), suggesting that factors
other than arterial diameter contribute to access
site failure. We have demonstrated that a radial
learning curve exists (4), and variables such as
operator experience, catheter manipulation, multi-
ple arterial punctures, catheter exchanges, and use
of sedation/vasodilator therapy can all impact RAS
and crossover rates.
The authors propose using pre-procedural ultra-
sound to aid in access site decisions. Although not
routinely used in the United States and not included
in the SAFE-PCI for Women trial protocol, pre-
procedural ultrasound may provide valuable infor-
mation using relatively inexpensive, portable, and
noninvasive technology. Theoretically, ultrasound
might also reduce access-related trauma. However,
arterial size is dynamic and is affected by variables
such as the degree of patient sympathetic tone and
use of intra-arterial vasodilators. The timing of use
of imaging and ultrasound-based triaging of patients
to access site strategy should account for these fac-
tors. Furthermore, the risks/beneﬁts of recommend-
ing a “femoral ﬁrst” strategy to avoid risk of radial
access failure should be weighed carefully against
the added bleeding risk associated with femoral ac-
cess. For example, in obese, short females with small
radial arteries, one might still attempt TRI ﬁrst.
Further understanding of the correlation between
radial artery size, spasm, and access failure should
be pursued before routine use of ultrasound toguide access decisions. The use of imaging for pre-
emptive crossover risk stratiﬁcation and to optimize
contemporary TRI should also be systematically
investigated in future studies.*Connie N. Hess, MD, MHS
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2277–86.Safety and Feasibility
of Transradial
Catheterization in
Breast Cancer Survivors
A 2-Center International ExperienceThe technical feasibility of transradial access (TRA) in
breast cancer survivors is usually not a concern; even
so, the perceived fear of lymphedema, both on the
part of the survivor and medical staff, is the limiting
factor. Cardiac catheterization and percutaneous cor-
onary intervention using TRA is associated with lower
rates of vascular and bleeding complications (1–3).
However, relegating breast cancer survivors to only
femoral access denies these beneﬁts of TRA to a large
group of predominantly female patients. Therefore,
the aim of this report is to describe the safety and
feasibility of TRA in patients with prior ipsilateral
breast cancer undergoing cardiac catheterization.
We retrospectively analyzed all breast cancer pa-
tients who underwent coronary catheterizations over
a 4-year (2009 to 2013) period from 2 academic,
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640tertiary-care institutions; one located in the United
States and the other in Quebec City, Quebec, Canada.
Both centers had >15 years of experience with trans-
radial catheterization. At the U.S. center, 4 of 5 op-
erators were experienced radialists, whereas the ﬁfth
operator’s default access was femoral with an overall
institutional TRA utilization of 65%. At the Canadian
center, 4 operators usually performed TRA in more
than 90% of the patients. The primary endpoint was
deﬁned as either the development of lymphedema,
soft tissue infection, and/or other vascular-related
complications within 30 days. The secondary
endpoint was any long-term complication, up to
4 years. The data were then collected by retrospective
chart review of the pre-existing electronic medical
records, regarding patient demographics, type of
breast cancer surgery (lumpectomy, partial/total
mastectomy), and whether they had axillary dissec-
tion and/or radiation therapy.
Qualitative variables were expressed as n (%)
and the quantitative variables as mean  SD. The
comparison of numerical variables was performed
using the Student t test. The chi-square test was used
to compare qualitative variables. The differences
were considered statistically signiﬁcant when a
p value was <0.05.
A total of 129 patientswere found to have a diagnosis
for both breast cancer and coronary catheterization
and underwent 134 procedures. The population was
then collated into an ipsilateral group (n ¼ 42 pro-
cedures) that had transradial catheterizations ipsilat-
eral to their breast cancer; and an alternate access
group (n ¼ 92 procedures) that had transradial cathe-
terizations contralateral to the breast cancer side or by
the transfemoral approach. Operator’s preference
(right radial access comfortability, radial inexperience,
presence of bypass grafts, left internal mammary
graft), or patient’s beliefs on the basis of the advice
from the breast surgeon were considered drivers for
the choice of access site. The ipsilateral group tended
to be younger than the alternate access group (66  10
years and 69  10 years, respectively, p ¼ 0.07), and
cancer therapy received by these patients was similar
across the study population. Baseline and procedural
characteristics as well as clinical outcomes of the study
groups are shown in Online Table 1. None of the pa-
tients had pre-existing arm lymphedema in either
group. Seven patients in the ipsilateral group had right
heart catheterization performed via a forearm vein on
the same side of the breast cancer. There were no re-
ports of access failure or technical difﬁculties during
the procedure, post-procedure lymphedema, and soft
tissue infection within 30 days and up to 4 years of
follow-up in either of the 2 groups. The alternate accessgroup had numerically more access site vascular
complications, (2 femoral hematomas, medically
managed) versus the ipsilateral group (p ¼ 0.54). Of
note, when all TRA (ipsilateral or contralateral, n ¼ 82)
patients were compared with the transfemoral (n ¼ 52)
cases regarding vascular complications, the TRA group
exhibited a strong trend towards lower complications
rate (p ¼ 0.073).
The major ﬁnding of this 2-center international
study reveals that transradial cardiac catheterization
can be safely performed on the ipsilateral side in
breast cancer patients without increasing the risk of
lymphedema or other vascular arm complications.
A common ritual to prevent lymphedema in breast
cancer patients is the avoidance of intravenous
catheters, needle sticks, or any potential trauma of
the ipsilateral arm, also including blood pressure
measurements (4). Lymphedema implies obstruction
of the lymphatic conduits, and arterial circulation is
typically not impaired. The effect on the venous
system is poorly understood, and whether venous
obstruction may be contributive is unclear. Interest-
ingly, our data included 7 patients who underwent
simultaneous right heart catheterization via the
forearm ipsilateral to cancer resections, and none of
these patients had any apparent adverse events.
Despite the lack of evidence for avoidance of the
ipsilateral arm, the radial access contralateral to the
cancer side may be preferred to avoid potential con-
ﬂicts with this sensitive patient issue. However, the
contralateral radial may not always be an option
(bilateral breast cancer, mammary graft with ipsilat-
eral breast cancer, surgical removal/occlusion of the
radial artery, and so on), and the operator may choose
femoral access and its associated increased risk of
vascular complications. In the present study, patients
in whom an alternate access site for catheterization
was chosen, less than one-half had a mastectomy.
Hence, patient instructions and warnings should be
tailored to the individual patient. Because the ma-
jority of breast cancer patients are women and at risk
of higher bleeding complications from femoral cath-
eterization, this known bleeding risk with strong
evidence needs to be weighed against the ritual
advice to prevent lymphedema before radial access is
denied.
The present study has limitations inherent to
retrospective data collections. No objective mea-
surements of the lymphedema such as arm circum-
ference or skin thickness were captured. However,
it is reassuring that there were no reports of clinically
signiﬁcant lymphedema from a patient population
that is in general sensitized to this potential compli-
cation. Although the results of this report are
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641encouraging, they are preliminary and do not have
the strength of evidence to completely redeﬁne risk
reduction behaviors for lymphedema. Prospective
larger studies are needed to address this concern.
Ipsilateral transradial cardiac catheterization can
be safely performed in breast cancer survivors
without increasing the risk of lymphedema or other
vascular arm complications.Pradeep K. Yadav, MD
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Restenosis in Patients
Treated With Thoracic
External Beam Radiation
for CancerWe read with interest the paper of Liang et al. (1)
about the outcomes of percutaneous coronary in-
terventions (PCI) with stents in patients undergoing
external beam thoracic radiation therapy (EBRT) for
cancer. The authors identiﬁed 115 patients treated
with EBRT a median 3.6 years after stenting (group
A) and 45 patients treated with EBRT a median2.2 years before stenting (group B), demonstrating
that long-term mean target lesion revascularization
rates in group A (3.2 vs. 6.6%; hazard ratio: 0.6; 95%
conﬁdence interval: 0.2 to 1.6; p ¼ 0.31) and
group B (9.2 vs. 9.7%; hazard ratio: 1.2; 95% conﬁ-
dence interval: 0.4 to 3.4; p ¼ 0.79) were similar to
rates in corresponding control patients (group A:
1,390 control patients; group B: 439 control pa-
tients). The authors concluded that thoracic EBRT is
not associated with increased stent failure rates
when used before or after PCI, and a history of PCI
should not preclude the use of curative thoracic
EBRT in cancer patients or vice versa. However,
restenosis is a complex process involving multiple
players, especially in patients with cancer. As re-
ported by the authors, the effect of EBRT on vascular
stents remains unclear, as both animal and human
studies have found variable effects of EBRT on pre-
venting stenosis in coronary and noncoronary arteries
after arterial injury and stenting. Moreover, in pa-
tients with cancer the administration of systemic
chemotherapy may also affect the restenotic process.
Of importance, some chemotherapy drugs (i.e.,
paclitaxel for breast cancer and non-small cell lung
cancer, ﬂudarabine for non-Hodgkin lymphoma) are
well-known antiproliferative agents with established
effects on vascular smooth muscle cells and also used
for drug-eluting stent technology to reduce neointima
proliferation (2,3). As a consequence, we think it
would be of interest to consider in the analysis the
effect of concomitant chemotherapy, in order to
clarify the role of thoracic EBRT on PCI outcomes in
patients with cancer.*Rocco A. Montone, MD
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